Alfteimi Ammar, Lützen Ulf, Helm Alexander, Jüptner Michael, Marx Marlies, Zhao Yi, Zuhayra Maaz
Department of Nuclear Medicine, Molecular Diagnostic Imaging and Therapy, University Hospital of Schleswig-Holstein (UKSH), Campus Kiel, Karl Lennert Cancer Center North, Feld-Str. 21 (Haus L), 24105, Kiel, Germany.
EJNMMI Radiopharm Chem. 2022 Jul 29;7(1):20. doi: 10.1186/s41181-022-00172-1.
The recent development of quinoline-based radiotracers, which act as fibroblast activation protein inhibitors (FAPIs), has shown promising preclinical and clinical advantages. [Ga]Ga-FAPI-46 is a new radiotracer for in vivo detection of the fibroblast activation protein by positron emission tomography (PET). Recently, the automated synthesis of [Ga]Ga-FAPI-46 was reported based on pre-concentration and purification of the generator eluate by using a cation exchange-cartridge. Our aim was to simplify the synthesis and shorten the automated synthesis of [Ga]Ga-FAPI-46 to make it accessible and thus even more attractive to a broader clinical and scientific community.
We developed and evaluated the GMP compliant automatic synthesis of [Ga]Ga-FAPI-46 using two different Ge/Ga generators (an Eckert & Ziegler, GalliaPharm generator, 1.85 GBq/50 mCi and an iThemba generator, 1.85 GBq/50 mCi) Somerset West, South Africa) and three different commercial and customized systems: the EasyOne module from Trasis; the GaSy module from Synthra with a customized synthesis template and a customized single use cassette. Additionally, the automatic synthesis of [Ga]Ga-FAPI-46 was established on a GallElut synthesis module from Scintomics with fixed tubing.
Independent of the synthesis modules or the generators employed we were able to complete the synthesis of [Ga]Ga-FAPI-46 in 12 min including the process of purification and formulation. In all cases, the final products showed more than 99.5% chemical purity and the radiochemical yield reached around 92.5% (decay corrected). All quality control parameters (e.g. sterility, stability and radiochemical purity) were conform to the European Pharmacopoeia.
作为成纤维细胞活化蛋白抑制剂(FAPIs)的喹啉基放射性示踪剂的最新进展已显示出有前景的临床前和临床优势。[镓]Ga-FAPI-46是一种用于通过正电子发射断层扫描(PET)在体内检测成纤维细胞活化蛋白的新型放射性示踪剂。最近,基于使用阳离子交换柱对发生器洗脱液进行预浓缩和纯化,报道了[镓]Ga-FAPI-46的自动化合成。我们的目标是简化[镓]Ga-FAPI-46的合成并缩短其自动化合成过程,使其更易于获得,从而对更广泛的临床和科学界更具吸引力。
我们使用两种不同的锗/镓发生器(一台Eckert & Ziegler公司的GalliaPharm发生器,1.85 GBq/50 mCi和一台iThemba发生器,1.85 GBq/50 mCi,南非萨默塞特韦斯特)以及三种不同的商业和定制系统开发并评估了符合GMP标准的[镓]Ga-FAPI-46自动合成方法:来自Trasis的EasyOne模块;来自Synthra的GaSy模块,带有定制的合成模板和定制的一次性试剂盒。此外,在Scintomics公司的带有固定管路的GallElut合成模块上建立了[镓]Ga-FAPI-46的自动合成方法。
无论使用何种合成模块或发生器,我们都能够在12分钟内完成[镓]Ga-FAPI-46的合成,包括纯化和制剂过程。在所有情况下,最终产品的化学纯度均超过99.5%,放射化学产率达到约92.5%(衰变校正)。所有质量控制参数(如无菌性、稳定性和放射化学纯度)均符合欧洲药典标准。